Main Menu

The technology at hand involves a rabbit polyclonal antibody specifically designed for the human Sun1 inner nuclear envelope protein, even though it is directed against the mouse Sun1 inner nuclear membrane protein. Sun1 is known to be an inner nuclear envelope protein, and defects in such proteins can lead to debilitating conditions like Emery-Dreifuss muscular dystrophy and Hutchinson Gilford Progeria Syndrome. Importantly, the antibody serves as a valuable tool for diagnostic and analytical studies concerning cells afflicted with nuclear envelope defects.

The technology in focus involves monoclonal antibody CI.11B11.B4.C4, a pioneering biological tool designed to target and bind with high specificity to both isoforms of mouse APOBEC3, mA3 and mA3d5. APOBEC3 proteins play a crucial role in innate immune defense against retroviruses by inducing hypermutation in the viral genome, thereby hindering viral replication and infection.

This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments.

The live-attenuated Nipah virus vaccines, based on recombinant Vesicular Stomatitis Virus (VSV) vectors, represent a groundbreaking approach to combating Nipah virus infections. These vaccines, expressing Nipah virus glycoprotein (G) or fusion protein (F), have demonstrated exceptional protective efficacy in animal models. Key advantages include their ability to replicate within the vaccinated individual, eliciting a robust immune response superior to non-replicating vaccine platforms.

The technology involves the development of a probiotic-based inhalational therapeutic for the prevention and treatment of acute respiratory virus infections. This innovative approach utilizes live or heat-inactivated cells of Lactobacillus plantarum, administered directly to the respiratory mucosa. This method has shown significant protection against lethal outcomes of respiratory virus infections by suppressing virus-induced proinflammatory cytokines.

The Ribopuromycylation (RPM) technology, developed by Dr. Jon Yewdell and Dr. Alexandre David, offers a powerful and universal method for visualizing and studying protein translation within cells. RPM involves the use of puromycin, a molecule that mimics a tyrosyl-tRNA and terminates translation by becoming covalently incorporated into the nascent protein chain's C-terminus within the ribosome's A site. This technique enables the immobilization of puromycylated nascent protein chains on ribosomes when chain elongation inhibitors like cycloheximide or emetine are utilized.

The developed technology is a high-affinity polyclonal antibody targeting BST-2, a crucial surface antigen involved in restricting the replication of HIV-1 and other enveloped viruses. This antibody, generated from recombinant BST-2 ectodomain protein, offers versatility in various research techniques, such as FACS, immunoblotting, immunofluorescence, and immunoprecipitation. Additionally, it exhibits bioactivity, effectively inhibiting BST-2 function in virus-producing cells.

This groundbreaking technology entails the utilization of genetically modified mice, specifically engineered to enable the non-destructive detection and isolation of cells actively transcribing the IL-4 and IL-13 genes. By expressing Amcyan and DsRed-DR fluorescent proteins under the control of these gene loci, researchers gain a powerful tool for studying cytokine gene expression without the need for cell death, offering significant advantages over traditional intracellular staining methods.

This technology introduces a groundbreaking method for discovering and isolating anti-idiotypic antibodies, with a primary focus on inhibiting or extinguishing the activity of VRCOl, a broadly neutralizing anti-HIV-1 antibody. These anti-idiotypic antibodies provide a vital mechanism for controlling adverse events that may result from therapeutic antibody administration. The innovative method involves immunizing animals with specific antibody fragments, followed by systematic selection and isolation of somatically mutated B cells.

This technology includes a set of noise controls in the form of structural modifications to the cutting drums used in underground coal mining. Longwall shearer operators are exposed to high levels of noise, i.e., above 98 dB(A), which are clearly well above the permissible exposure level of 90 dB(A). In an effort to reduce this noise exposure, research was conducted that identified the longwall cutting drums as the most significant sound radiating components.